Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies

publication date: Aug 16, 2023

Singapore CytoMed Therapeutics signed a Memorandum of Understanding that, if finalized, would allow the company to use Hangzhou CNK Therapeutics’ PiggyBac technology. The PiggyBac technology would be used to permanently graft Chimeric Antigen Receptor (CAR) genes into gamma delta (γδ) T cells via a non-viral gene editing method. As a result, CAR gene expression is expected to continue for as long as the γδ T cells are present in the body, potentially increasing the therapeutic effect. The two companies may also form a JV to conduct clinical trials in China. More details....

Stock Symbol: (NSDQ: GDTC)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital